Showing results (281-290 of 392) with videos related to
Sort By:
Pageof 40
Leukemia|June 25, 2021
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendationsWilliam G Wierda, Andrew Rawstron, Florence Cymbalista, et al.The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.Blood|March 25, 2020
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclaxEugen Tausch, Christof Schneider, Sandra Robrecht, et al.The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.Nature Medicine|December 9, 2023
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trialOthman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, et al.The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.The Lancet. Oncology|February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialAndrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.Pageof 40